List of Fibricor drug patents
Fibricor is owned by Athena.
Fibricor contains Fenofibric Acid.
Fibricor has a total of 4 drug patents out of which 0 drug patents have expired.
Fibricor was authorised for market use on 14 August, 2009.
Fibricor is available in tablet;oral dosage forms.
Fibricor can be used as adjunctive therapy to diet in patients with hyperlipidemias, adjunctive therapy to diet in patients with hyperlipidemias; adjunctive therapy to diet in patients with mixed dyslipidemia; adjunctive therapy to diet to patients with hypertriglyceridemia, adjunctive therapy to diet in patients with mixed dyslipidemia; adjunctive therapy to diet in patients with elevated cholesterol and/or lipid levels, adjunctive therapy to diet to patients with hypertriglyceridemia.
The generics of Fibricor are possible to be released after 20 August, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7569612 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(4 years from now) | |
| US7741374 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(4 years from now) | |
| US7741373 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(4 years from now) | |
| US7915247 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(4 years from now) | |
Drugs and Companies using FENOFIBRIC ACID ingredient
Market Authorisation Date: 14 August, 2009
Treatment: Adjunctive therapy to diet in patients with hyperlipidemias; Adjunctive therapy to diet in patients with mixed dyslipidemia; Adjunctive therapy to diet in patients with elevated cholesterol and/or lip...
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic